Key Insights

Highlights

Success Rate

85% trial completion

Published Results

30 trials with published results (21%)

Research Maturity

94 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

11.0%

16 terminated out of 145 trials

Success Rate

85.5%

-1.1% vs benchmark

Late-Stage Pipeline

32%

46 trials in Phase 3/4

Results Transparency

32%

30 of 94 completed with results

Key Signals

30 with results85% success16 terminated

Data Visualizations

Phase Distribution

98Total
Not Applicable (19)
Early P 1 (2)
P 1 (11)
P 2 (20)
P 3 (23)
P 4 (23)

Trial Status

Completed94
Terminated16
Unknown15
Recruiting9
Not Yet Recruiting4
Withdrawn4

Trial Success Rate

85.5%

Benchmark: 86.6%

Based on 94 completed trials

Clinical Trials (145)

Showing 20 of 20 trials
NCT04798690RecruitingPrimary

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

NCT04615273Phase 3CompletedPrimary

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04614337Phase 2CompletedPrimary

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

NCT03226821Phase 4Terminated

Body Composition and Adipose Tissue in HIV

NCT05250063Phase 2CompletedPrimary

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

NCT07173036Not ApplicableNot Yet RecruitingPrimary

Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels

NCT05820672RecruitingPrimary

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05681299Phase 4Recruiting

Effects of GH and Lirglutide on AgRP

NCT05775523RecruitingPrimary

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT00227253Recruiting

Chromosome 18 Clinical Research Center

NCT03422081CompletedPrimary

Growth and Asymmetric diMethylArginine

NCT04020913CompletedPrimary

Skeletal Muscle Effects of GH in Boys

NCT06294860CompletedPrimary

Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy

NCT05645211Not Yet RecruitingPrimary

The AgRP and GH/IGF-1 Axis in Children

NCT03225755CompletedPrimary

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

NCT03500913CompletedPrimary

Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03525587Not ApplicableCompletedPrimary

Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency

NCT06709040Enrolling By InvitationPrimary

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

NCT02243852WithdrawnPrimary

Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)

NCT06694506Not ApplicableNot Yet RecruitingPrimary

BELux Children OutcoME During A(@)Dulthood With GHD

Scroll to load more

Research Network

Activity Timeline